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Introduction
Protease-activated receptor 2 (PAR2), which is mainly activated by trypsin (one of the serine proteases), has been shown to cause delayed barrier repair in the skin (Feingold et al. 2007) , inflammatory responses (Seeliger et al. 2003) and vasodilatation in the large arteries (Robin et al. 2003) . Protease-activated receptor 2 exists widely in human skin, including endothelial cells of skin vessels (Steinhoff et al. 1999 and eccrine sweat glands (Bovell et al. 2009; Böttcher-Haberzeth et al. 2013; Shin et al. 2015) . Therefore, PAR2 may be involved in the regulation of cutaneous vascular and sweating responses. However, whether and how PAR2 activation may mediate cutaneous vasodilatation and sweating in humans in vivo remains to be determined.
Nitric oxide synthase (NOS) and cyclo-oxygenase (COX) are two key enzymes that can modulate cutaneous vascular tone (Holowatz et al. 2005; Kellogg et al. 2005; McCord et al. 2006; Lenasi & Strucl, 2008; McNamara et al. 2014; Cavka et al. 2015) as well as sweating (Lee & Mack, 2006; Welch et al. 2009; Fujii et al. 2014; Stapleton et al. 2014) . To the best of our knowledge, no study has investigated whether these enzymes contribute to cutaneous vasodilatation and sweating in response to PAR2 activation. One previous study reported that both NOS and COX contribute to PAR2-mediated vasodilatation in conduit arteries as assessed by forearm venous occlusion plethysmography in humans in vivo (Robin et al. 2003) . Likewise, stimulation of PAR2 may directly cause cutaneous vasodilatation via NOS and COX. With respect to sweat glands, a study using a human sweat gland cell line in vitro showed that increased activity of PAR2 results in an increase in intracellular Ca 2+ (Bovell et al. 2009 ). However, these findings should be interpreted with caution given that the sweat glands underwent a process of viral transformation, which would have altered normal receptor function. If an increase in intracellular Ca 2+ in response to PAR2 activation is induced in vivo, this can activate NOS (Busse & Mülsch, 1990) . Furthermore, it can stimulate phospholipase A2, which in turn breaks down phospholipids, creating arachidonic acid, which is a precursor of COX-derived prostanoids (Leslie, 1997) . Hence, PAR2 activation might increase sweating via NOS-and COX-dependent mechanisms.
In this study, we evaluated the effect of augmented PAR2 activity on cutaneous vascular and sweating responses in normothermic resting humans in vivo. We hypothesized that increased activity of PAR2 directly induces cutaneous vasodilatation and sweating, and that NOS and COX mediate this response.
Methods

Ethical approval
The study was approved by the University of Ottawa Health Sciences and Science Research Ethics Board, meeting the guidelines set forth by the Declaration of Helsinki. Verbal and written informed consent were obtained from all volunteers before their participation in the study.
Subjects
Twelve physically active, healthy young men participated in the study. Their physical characteristics were as follows (mean ± SD): body mass, 76.9 ± 13.4 kg; height, 1.73 ± 0.05 m; and age, 29 ± 5 years. All subjects were non-smokers and not taking prescribed medications.
Experimental design
All subjects were instructed to abstain from taking over-the-counter medications (including non-steroidal anti-inflammatory agents and vitamins) for at least 48 h before the study, as well as from alcohol and caffeine consumption for at least 12 h before. Subjects refrained from performing strenuous exercise on the day before the study. On the day of the experiment, subjects did not consume any food for at least 2 h before and throughout the study. Upon arrival, the subjects voided their bladder, and their body mass was measured using a digital weight scale platform (Model CBU150X; Mettler Toledo Inc., Columbus, OH, USA). The subjects' body height was measured using an eye-level physician stadiometer (Model 2391; Detecto Scale Company, Webb City, MO, USA). Thereafter, subjects were seated in a semi-recumbent position in a thermoneutral room (ß23°C) and were equipped with four intradermal microdialysis fibres (30 kDa cut-off, 10 mm membrane; MD2000; Bioanalytical Systems, West Lafayette, IN, USA) placed on the dorsal side of the dermal layer of the forearm skin (left side), with a separation of at least 4.0 cm between each fibre. The intersite distance of 4.0 cm is sufficient to eliminate any between-site contamination of the administered agents (Meade et al. 2016) . With an aseptic technique, a 25 gauge needle was first inserted into the non-anaesthetized skin, then a microdialysis fibre was threaded through the lumen of the needle. The needle was subsequently withdrawn, leaving only the fibre in place. The entry and exit points were separated by ß2.5 cm, and the microdialysis fibres were secured with surgical tape.
Approximately 10 min after the completion of fibre insertion, the four microdialysis fibres were continuously perfused in a counterbalanced manner with the following: Protease-activated receptor 2 in cutaneous vasodilatation and sweating (i) lactated Ringer's solution (Baxter, Deerfield, IL, USA) as a control site; (ii) 10 mM N G -nitro-L-arginine (Sigma-Aldrich, St Louis, MO, USA), a non-selective NOS inhibitor; (iii) 10 mM ketorolac (Sigma-Aldrich), a non-selective COX inhibitor; or (iv) a combination of the NOS and COX inhibitors. To account for the potential influence of fibre placement and continuous fluid perfusion, the control site also had a microdialysis fibre inserted with continuous perfusion of lactated Ringer's solution. These concentrations were determined from previous studies in which intradermal microdialysis was used in human skin for N G -nitro-L-arginine (Medow et al. 2007; Brunt et al. 2015) and ketorolac (Holowatz et al. 2005; Kellogg et al. 2005) . Each drug was continuously perfused at a rate of 4.0 µl min −1 for at least 75 min to ensure the establishment of each inhibition. Perfusion continued for the entire experimental protocol until the procedure for maximal cutaneous vasodilatation began (see next paragraph).
After a minimum of 75 min after the administration of the inhibitors, 10 min of baseline data were collected. This time period (ࣙ75 min) has been shown to be sufficient to ensure that any potential influence of tissue trauma from the insertion of the fibre has subsided (Anderson et al. 1994) . Subsequently, each microdialysis fibre was co-perfused with the PAR2 agonist SLIGKV-NH 2 (Alomone labs, Jerusalem, Israel) in a dose-ascending manner, with five different concentrations of 0.06, 0.18, 0.55, 1.66 and 5 mM at a rate of 4.0 µl min −1 (each for 25 min), in combination with the site-specific pharmacological agents. After completing the five-dose infusion protocol, the administration of 50 mM sodium nitroprusside (Sigma-Aldrich) was initiated at each microdialysis site at a rate of 6.0 µl min −1 to achieve maximal cutaneous vasodilatation. The sodium nitroprusside administration lasted for approximately 20-30 min until a stable plateau for a minimum of 5 min was achieved.
Measurements
A sweat capsule covering an area of 1.1 cm 2 specifically designed for use with an intradermal microdialysis probe (Meade et al. 2016) was placed over the centre of each microdialysis membrane. The sweat capsules were secured to the skin with adhesive rings and topical skin glue (Collodion HV; Mavidon Medical Products, Lake Worth, FL, USA). Dry compressed air from a gas tank located in the thermoneutral room (ß23°C) was supplied to each capsule at a rate of 0.20 l min −1 , while water content of the effluent air from the sweat capsule was measured with high-precision dew point mirrors (model 473; RH Systems, Albuquerque, NM, USA). Local forearm sweat rate was calculated every 5 s from the difference in water content between influent and effluent air multiplied by the flow rate and normalized for the skin surface area under the capsule (in milligrams per minute per square centimetre). Integrated laser-Doppler flowmetry probes with a seven-laser array (model 413; Perimed, Stockholm, Sweden) were housed in the centre of each sweat capsule over each microdialysis fibre to measure cutaneous red blood cell flux (an index of cutaneous blood flow, expressed in perfusion units) at a sampling rate of 32 Hz, as assessed by laser-Doppler flowmetry (PeriFlux System 5000; Perimed). One trained experimenter measured blood pressures every 10-15 min by manual auscultation using a mercury column sphygmomanometer (Baumanometer Standby Model; WA Baum Co., Copiague, NY, USA). Mean arterial pressure was calculated as diastolic arterial pressure plus one-third of the difference between systolic and diastolic pressures (i.e. pulse pressure). Cutaneous vascular conductance (CVC) was evaluated as the cutaneous red blood cell flux divided by mean arterial pressure to account for changes in tissue perfusion pressure.
Data analysis
The CVC data were presented as a percentage of the maximum using absolute maximal CVC data obtained during sodium nitroprusside administration. This normalization of CVC minimizes between-site differences in the level of cutaneous blood flow, thereby enabling a between-site comparison of CVC (Johnson et al. 2014) . All CVC and sweat rate data used for data analysis were obtained by averaging values over the last 5 min of each stage (i.e. baseline, 0.06, 0.18, 0.55, 1.66 and 5 mM of SLIGKV-NH 2 ).
Statistical analysis
All statistical analyses were conducted using the software package SPSS 24 for Windows (IBM, Armonk, NY, USA). Cutaneous vascular conductance (as a percentage of the maximum) and sweat rate (in milligrams per minute per square centimetre) were analysed using a two-way repeated-measures ANOVA with factors of treatment site (four sites) and stage (baseline and five doses of SLIGKV-NH 2 ). One-way repeated-measures ANOVA was used to analyse absolute maximal CVC (in perfusion units per millimetre of mercury) obtained during sodium nitroprusside administration, with a factor of treatment site (four sites). When detecting a significant interaction, simple main effect tests were performed. When a main effect was detected, post hoc multiple comparisons were carried out using a modified Bonferroni test (i.e. Hochberg's procedure; Hochberg, 1988) . The level of significance for all analyses was set at P ࣘ 0.05. All values are reported with a mean ± SD.
Results
The CVC data are presented in Fig. 1 . Administration of 5 mM SLIGKV-NH 2 significantly increased CVC at all skin sites (all P ࣘ 0.01). Cutaneous vascular conductance measured during administration of ࣙ0.55 mM SLIGKV-NH 2 was lower with NOS inhibition in relationship to the control site regardless of the presence or absence of co-administration of the COX inhibitor (all P ࣘ 0.05). There was no difference in CVC between NOS inhibition alone versus NOS plus COX inhibition sites throughout the protocol (all P > 0.05). COX inhibition alone did not modulate CVC compared with the control site at baseline and any dose of SLIGKV-NH 2 (all P > 0.05). Absolute maximal CVC obtained during sodium nitroprusside administration did not differ between sites (P > 0.05). Sweat rate was not increased from baseline by any dose of SLIGKV-NH 2 administered (all P > 0.05). Responses were evaluated at four intradermal forearm skin sites treated with the following: (i) lactated Ringer's solution (control; circles); (ii) nitric oxide synthase (NOS) inhibition (triangles); (iii) cyclo-oxygenase (COX) inhibition (diamonds); or (iv) NOS and COX inhibition (squares). * Control versus NOS inhibition plus control versus NOS + COX inhibition (P ࣘ 0.05). Cutaneous vascular conductance did not differ between the control and COX inhibition sites or between NOS inhibition and NOS + COX inhibition sites throughout (all P > 0.05). Data are presented as mean values ± SD.
Discussion
We are the first to demonstrate that PAR2 activation directly mediates cutaneous vasodilatation, but not sweating, in resting normothermic humans in vivo. We also demonstrate that NOS, but not COX, contributes to the cutaneous vasodilatation associated with the activation of PAR2.
Cutaneous vascular response
Our results demonstrate that PAR2 activation induced by 5 mM SLIGKV-NH 2 directly stimulates cutaneous vasodilatation (Fig. 1) . Likewise, an elevation in PAR2 activity elicited by SLIGKV-NH 2 has been previously shown to increase blood flow in human forearm conduit arteries in vivo (Robin et al. 2003; Gudmundsdóttir et al. 2006) . Importantly, we evaluated the enzymatic mechanisms underpinning the regulation of PAR2-induced cutaneous vasodilatation for the first time, revealing that NOS contributes to the response (Fig. 1 ). It may be that SLIGKV-NH 2 activates PAR2 located on the endothelial cells of cutaneous blood vessels (Steinhoff et al. 1999 , which may lead to subsequent increases in intracellular Ca 2+ through inositol trisphosphate-dependent mechanisms, as observed in mice in vitro (Hennessey et al. 2015) . If an intracellular elevation of Ca 2+ occurred, this could contribute to the NOS-dependent PAR2-induced cutaneous vasodilatation, because Ca 2+ is known to activate NOS (Busse & Mülsch, 1990) . In contrast to our findings with NOS, we were unable to observe a functional contribution of COX to the regulation of cutaneous vasodilatation during PAR2 activation (Fig. 1) .
Our finding pertaining to the contribution of NOS to the PAR2-induced cutaneous vasodilatation is consistent with a comparable response observed in forearm conduit arteries (Robin et al. 2003) . However, Robin et al. (2003) also found that COX contributes to PAR2-induced forearm vasodilatation, which is in contrast to the lack of contribution of COX found in the present study. Taken together, these observations suggest that differential mechanisms underlying PAR2-induced vasodilatation exist between conduit arteries versus the microcirculation, such as the vessels found in skin. Although we cannot elucidate the mechanisms underpinning these disparate responses, a differential regulation of vascular tone between conduit arteries and skin vessels has been observed for other vasodilatory stimuli. For example, flow-mediated vasodilatation is linked to NOS in the forearm conduit arteries (Green et al. 2014) but not in skin microcirculation (Wong et al. 2003) .
Protease-activated receptor 2-mediated cutaneous vasodilatation was not abolished by a simultaneous inhibition of NOS and COX (Fig. 1) . Thus, other mechanisms should also be involved in this vasodilatory response. In vitro studies have demonstrated that PAR2-induced vasorelaxation is attributed to Ca 2+ -activated K + channels (McGuire et al. 2002; Kawabata et al. 2003; Kagota et al. 2011) ; thus, K + channels may also underlie the PAR2-induced cutaneous vasodilatation. Moreover, perivascular adipose tissues have been shown to be involved in the PAR2-induced vasorelaxation response, as demonstrated in the aortic rings of mice (Li et al. 2011) . Similar mechanisms may be involved in PAR2-induced cutaneous vasodilatation, and this requires future scrutiny.
Sweating response
In contrast to our study hypothesis, the administration of SLIGKV-NH 2 did not increase sweat rate in humans in vivo at any dose used in the present study. Thus, PAR2 located in eccrine sweat gland cells (Bovell et al. 2009; Shin et al. 2015) does not appear to increase sweat production directly. This response is inconsistent with in vitro studies demonstrating that PAR2 activation with SLIGKV-NH 2 increases intracellular Ca 2+ , which is a major ion responsible for sweat secretion (Sato & Sato, 1981; Metzler-Wilson et al. 2014) . It has also been reported that PAR2 activation with either trypsin or SLIGKV-NH 2 can regulate Cl − secretion in human sweat glands in vitro (Bovell et al. 2008) , a process which is also involved in the secretion of sweat (Cui et al. 2012; Ertongur-Fauth et al. 2014; Wilson & Metzler-Wilson, 2015) . We do not know why an elevation in sweat rate by PAR2 in resting normothermic humans in vivo was not detected. It may be that PAR2 located in eccrine sweat glands contributes to responses other than sweat secretion. For example, PAR2 may be involved in the terminal differentiation of eccrine sweat glands (Shin et al. 2015) . Furthermore, PAR2 activation may also play a role in protection against bacterial infection by the production and/or secretion of antibiotic peptides, such as dermcidin (also known as proteolysis-inducing factor; Schittek et al. 2001) , as PAR2 has been shown to mediate the expression of antibiotic peptides (Lee et al. 2010) . Clearly, further research is warranted to elucidate the functional role of PAR2 in sweat glands.
Considerations
We used synthetic activating peptide (SLIGKV-NH 2 ) to activate PAR2. However, PAR2 appears to be activated primarily by trypsin endogenously. It should be noted that the physiological response(s) associated with activation of PAR2 differ(s) between SLIGKV-NH 2 and trypsin (Bovell et al. 2009 ). This is evidenced by the fact that increases in Ca 2+ in response to trypsin cannot be repeated with subsequent administration, whereas this response can be reproduced with repeated infusion of SLIGKV-NH 2 . Given the significant tachyphylaxis that can occur with trypsin, activation of PAR2 with trypsin may attenuate the capacity of the cutaneous vessels to dilate. Hence, had we used other PAR2 agonists, such as trypsin, our results might have differed from our present observations. An important factor that must be considered as it relates to the role of PAR2 in the modulation of cutaneous vasodilatation and sweating is the possibility that the concentration of the drug at the target tissue may have been diluted from the original concentration administered. A reduction in the drug concentration would occur if not all of the drug is filtered throughout the microdialysis membrane and/or if the administered drug is diluted by the interstitial fluid under the underlying tissue.
In the present study, we can assess the activation of the sweat gland based only on the measurement of sweat gland output (i.e. as defined by an increase in sweat rate). It is possible that the activation of the sweat gland may have occurred without a measurable change in sweat output. In this case, the sweat produced in the lumen of the sweat gland may be reabsorbed such that net sweat output measured at the skin surface remains unchanged. Thus, our findings of a lack of a PAR2-mediated increase in sweating should be viewed in the context of our ability to measure changes in sweat output at the skin surface only.
Clinical implications
Protease-activated receptor 2 is known to mediate several inflammatory responses in the skin, including redness (cutaneous vasodilatation). Skin redness associated with the inflammatory response can occur as a result of sunburn because of prolonged exposure to sunlight (solar radiation), acne, viral infection and any type of dermatitis (e.g. atopic, allergic-contact and irritant-contact dermatitis). The increased CVC in response to the PAR2 agonist observed in the present study potentially mimics the redness associated with the above conditions. A previous study has shown that inflammatory responses in skin, including swelling, plasma extravasation and leucocyte adherence, associated with PAR2 activation are reportedly diminished by NOS inhibition, indicating a crucial role of NOS in the PAR2-induced inflammatory responses in the skin (Seeliger et al. 2003) . Our results extend our knowledge pertaining to PAR2-induced skin inflammation by demonstrating that NOS may play a pivotal role in the cutaneous vasodilatation associated with PAR2-induced skin inflammation. Therefore, it appears that NOS inhibition might have a therapeutic benefit in the treatment of skin inflammation, including redness. In contrast, our results imply that COX inhibitors, such N. Fujii and others as non-steroidal anti-inflammatory drugs, might not be effective in treating skin inflammation.
Protease-activated receptor 2 might be an important therapeutic target in the treatment of vascular dysfunction, because the PAR2-induced vasodilatation response is well preserved or even increased in the presence of endothelial dysfunction (Kagota et al. 2016) . Activation of PAR2 has also been shown to counteract the endothelin-1-induced vasoconstrictor effect (Roviezzo et al. 2016) . Endothelin-1 is a potent vasoconstrictor peptide involved in several pathophysiological conditions, such as hypertension. In line with this idea, we show that PAR2 activation can induce a cutaneous vasodilatory effect in part attributable to NO, an important cardioprotective molecule. Hence, augmenting PAR2 function might be a promising strategy to ameliorate microvascular dysfunction. Further research is warranted to evaluate whether microvascular dysfunction associated with ageing (Holowatz et al. 2006) , obesity (Patik et al. 2016) , cigarette smoking (Fujii et al. 2013; Moyen et al. 2015) , type 2 diabetes (Wick et al. 2006) , polycystic ovary syndrome (Wenner et al. 2013) and other chronic health conditions is improved by PAR2 activation.
Conclusion
We show that PAR2 activation with SLIGKV-NH 2 directly mediates cutaneous vasodilatation, but not sweating, in resting normothermic humans in vivo. We also demonstrate that NOS, but not COX, contributes to cutaneous vasodilatation in response to activation of PAR2.
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